News
News

The latest updates from AFAR.

Board Member in the News: Rudolph Tanzi on new class of Alzheimer's drugs in EBioMedicine

Oct 24
2017

Board Member in the News: Rudolph Tanzi on new class of Alzheimer's drugs in EBioMedicine View MoreBACK

In its October 2017 issue, EBioMedicine, an open-access journal jointly published by Cell Press and The Lancet, published research co-authored by AFAR Board member Rudolph E. Tanzi,PhD, on a novel class of drugs that more precisely blocks production of toxic forms of beta-amyloid linked to Alzheimer’s disease.

In the article, “Soluble Gamma-secretase Modulators Attenuate Alzheimer's β-amyloid Pathology and Induce Conformational Changes in Presenilin 1,” Tanzi and his co-authors have characterized a new class of drugs as potential therapeutics for Alzheimer's disease and discovered a piece in the puzzle of how they would work. Their study, using disease-related animal and cellular models, shows that treatment with a representative compound of this class of gamma-secretase modulators leads to a reduction of the Alzheimer's-associated beta-amyloid.

The original study can be read here.

A related article in Science Daily can be read here.


Rudolph E. Tanzi, Ph.D. is the Director, Genetics and Aging Research Unit at Mass General Institute for Neurodegenerative Disease and the Joseph P. and Rose F. Kennedy Professor of Neurology at Harvard Medical School.

 





View MoreBACK TO TOP